Hello my dears here is a great profit growth at an acceptable P/E ratio.
In the USA, demand for Krystal Biotech's gene therapy Vyjuvek is already extremely high. No wonder, the product is a game changer for the treatment of epidermolysis bullosa dystrophica (EBD), also known as "butterfly disease". Now sufferers in Europe can also justifiably hope for approval in the near future.
This is because Krystal Biotech has received a positive vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which supports EU approval of Vyjuvek. Now all that remains is for the European Commission to give the final green light. Krystal Biotech expects the decision in the second quarter of the current year.
"We are delighted to be able to offer DEB patients the first treatment that corrects the genetic defect and really changes their lives," says Dr. Cristina Has, Professor and Head of the Clinic for Genodermatoses in the Department of Dermatology at the University of Freiburg, looking optimistically towards approval. "Vyjuvek is a milestone because it addresses the first stage of the complex pathophysiology of DEB. It is amazing how simple and non-invasive it is to use, even in infants."
In May 2023, the US Food and Drug Administration (FDA) has already granted marketing authorization for Krystal Biotech's gene therapy. The launch went so well that the biotech company even reported earnings per share of USD 3.12 for 2024. Turnover increased by a whopping 473% to 290.5 million dollars compared to 2023.
CONCLUSION
Vyjuvek has quickly led Krystal Biotech into the black. This is despite the fact that the company is pushing ahead with other exciting pipeline assets that are cost-intensive. Larger setbacks remain interesting entry opportunities for speculative investors with the current SHAREHOLDER recommendation (up 157% since its launch in mid-February 2023).
